Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Needham initiated coverage on Cartesian Therapeutics Inc (NASDAQ:RNAC), a private company that went public in November following its reverse merger/ private placement financing with Selecta Biosciences.
尼德姆開始對Cartesian Therapeutics Inc（納斯達克股票代碼：RNAC）進行報道。該公司是一傢俬營公司，在與Selecta Biosciences進行反向合併/私募融資後，於11月上市。
Cartesian is developing re-dosable mRNA CAR-Ts for autoimmune disease. RNA CARTs don't require prior lymphodepletion and can, therefore, access a broader patient pool than most other cell therapies that require Cy/Flu.
笛卡爾正在開發用於自身免疫性疾病的可重複劑量的mRNA car-TS。與大多數其他需要Cy/Flu的細胞療法相比，RNA CART不需要事先進行淋巴消耗，因此可以獲得更廣泛的患者群。
Descartes-08, a lead candidate from Cartesian, is a personalized anti-BCMA CAR-T therapy designed for treating myasthenia gravis (MG), a rare disorder affecting approximately 130,000 patients in the U.S. and EU5 combined.
笛卡爾-08是笛卡爾的主要候選藥物，是一種個性化的抗BCMA CAR-T療法，專爲治療重症肌無力（MG）而設計，重症肌無力（MG）是一種罕見的疾病，在美國和歐盟五國共影響約13萬名患者。
The current standard of care (SOC) for MG involves drugs targeting acetylcholine receptors (AChR), steroids, and immunosuppressants, but they often lose effectiveness over time or lead to adverse effects.
MG目前的護理標準（SOC）涉及靶向乙酰膽鹼受體（AchR）、類固醇和免疫抑制劑的藥物，但它們通常會隨着時間的推移而失去療效或導致不良反應。
A recently approved medication, Argenx SA's (NASDAQ:ARGX) Vyvgart, has shown significant success in MG, generating approximately $1.1 billion in sales in FY2023.
最近批准的一種藥物Argenx SA（納斯達克股票代碼：ARGX）Vyvgart在MG領域取得了巨大成功，FY2023 的銷售額約爲11億美元。
Early data on Descartes-08 indicates promising results, suggesting deeper and longer-lasting effectiveness in MG-ADL (Myasthenia Gravis-Activities of Daily Living) compared to Vyvgart.
Descartes-08的早期數據顯示出令人鼓舞的結果，表明與Vyvgart相比，MG-ADL（重症肌無力日常生活活動）的療效更深、更持久。
Patients treated with Descartes-08 experienced clinical benefits lasting up to 9 months after the last infusion, whereas Vyvgart typically offers benefits lasting only 1-2 months post-infusion.
接受Descartes-08治療的患者在最後一次輸液後獲得長達9個月的臨床益處，而Vyvgart通常在輸液後僅持續1-2個月。
The analyst initiated coverage with a Buy rating and a price target of $42.
該分析師以買入評級和42美元的目標股價啓動了報道。
Phase 2b study data readout expected in mid-2024 will be a crucial driver for Cartesian Therapeutics' stock.
預計將於2024年中期公佈的2b期研究數據將成爲Cartesian Therapeutics股票的關鍵驅動力。
Needham says that Descartes-08 could capture a substantial share of the moderately to severely affected myasthenia gravis market because of its potent and long-lasting clinical effects compared to the current standard of care.
尼德姆說，Descartes-08可以在受中度至重度影響的重症肌無力市場中佔據相當大的份額，因爲與目前的護理標準相比，Descartes-08具有強大而持久的臨床效果。
The analyst projections suggest that Descartes-08 could achieve peak sales of approximately $4.3 billion by 2037, assuming it penetrates around 30% of the market.
分析師的預測表明，Descartes-08可以滲透到約30％的市場份額，到2037年達到約43億美元的峯值銷售額。
The proforma cash, cash equivalents, and restricted cash of approximately $118.3 million as of December 31, 2023, is expected to support planned operations into the second half of 2026.
截至2023年12月31日，預計現金、現金等價物和限制性現金約爲1.183億美元，將爲2026年下半年的計劃運營提供支持。
Price Action: RNAC shares are up 14.58% at $16.03 on the last check Wednesday.
價格走勢：在週三的最後一次支票中，RNAC股價上漲14.58％，至16.03美元。
Illustration of Phrama lab worker created with MidJourney.
使用 MidJourney 創作的 Phrama 實驗室工作人員的插圖。
譯文內容由第三人軟體翻譯。